Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GI 101

Next Previous
Drug Profile

GI 101

Alternative Names: GI-101; SIM-323; SIM0323

Latest Information Update: 15 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GI Innovation
  • Developer GI Innovation; Simcere Pharmaceutical Group
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 31 May 2024 Preclinical trials in Haematological malignancies (Combination therapy) in South Korea (Parenteral)
  • 31 May 2024 Updated pharmacodynamics data from a preclinical trial in Haematological malignancies and Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top